Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride

Abstract Background Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) leads to multiple metabolic changes, reduction in glucose levels and body weight are well established. In people with type 2 diabetes, GLP-1 RAs reduce the risk of cardiovascular (CV) disease and may also potent...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	J. Jendle, T. Hyötyläinen, M. Orešič, T. Nyström
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	BMC 2021-12-01
Reeks:	Cardiovascular Diabetology
Onderwerpen:	Ceramide Glimepiride GLP-1 receptor agonist Lipidomics Liraglutide Metabolomics
Online toegang:	https://doi.org/10.1186/s12933-021-01431-2
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!